Home > Resources > Company Profiles > Gilead Sciences, Incorporated

Gilead Sciences, Incorporated (GILD)

Email Confirmation

Dr.John C. Martin, M.D. , CEO/Director/Chairman of the Board

www.gilead.com

Industry: Healthcare

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

News Feeds

Final Glance: Biotechnology companies AP
Sep 05 2008
Midday Glance: Biotechnology companies AP
Sep 05 2008
Early Glance: Biotechnology companies AP
Sep 05 2008
Last Call: Gilead Sciences slips after downgrade AP
Sep 02 2008
FDA approves Gilead AIDS drug for hepatitis B AP
Aug 11 2008

Press Releases

BeaconEquity.com Issues Technical Trade Alerts on BioPharmaceutical Stocks: CEGE, AMLN, DNA, GENZ, AMGN, GILD Aug-29-2008, 10:50AM EDT
Gilead Sciences to Present at the Thomas Weisel Partners Healthcare Conference on Wednesday, September 3 Aug-27-2008, 04:15PM EDT
BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD Aug-18-2008, 10:20AM EDT
Seven Summits Research Releases Alerts on GOOG, MS, GILD, MMM, and AGU Aug-11-2008, 09:31AM EDT
Gilead Sciences and Merck & Co., Inc. Enter Into an Agreement to Register and Distribute HIV Medication Atripla(R) (Efavirenz 600 mg/ Emtricitabine 200 mg/ Tenofovir Disoproxil Fumarate 300 mg) in Twelve Countries Aug-01-2008, 08:30AM EDT

News From Around the Web

News

Storm, Economy Drag Down Energy ETFs (SmartMoney)

Sep 05 2008
Early Glance: Biotechnology companies (Boston Globe)

Sep 05 2008
Gilead Sciences Picks Up Volume, Hits 5-Month Low (RTTNews)

Sep 05 2008
Midday Glance: Biotechnology companies (Boston Globe)

Sep 04 2008
Biotechnology companies shares mixed at noon (Canadian Business Online)

Sep 03 2008
Gilead Sciences To Present At Thomas Weisel Partners Healthcare Conference; Webcast At 10:55 AM (RTTNews)

Sep 03 2008
Last Call: Gilead Sciences slips after downgrade (Boston Globe)

Sep 02 2008

Blogs

Serious Money: The business of politics and vice versa (Blogging Stocks)

Sep 03 2008
Brazil Rejects Gilead Patent On HIV Drug (Pharmalot)

Sep 03 2008
10 stocks for next 10 years, best credit cards & 12 ways to build a great credit score - Today in Money 9/3 (Blogging Stocks)

Sep 03 2008
Analyst calls: SCRX, GOOG, LOW, DF, GILD, EK, SOLR, XRX ... (Blogging Stocks)

Sep 02 2008

Employees

Number of Employees: 2,979

Revenue per Employee: $1,681,926

Top Executives

Dr.John J. Toole, Divisional Senior VP

Dr.William A. Lee, Divisional Senior VP

Dr. John F. Milligan, Ph.D., COO/President

James R. Meyers, Senior VP, Divisional

Dr. Norbert W. Bischofberger, Ph.D., Executive VP, Divisional/Chief Scientific Officer

Kevin Young, Divisional Executive VP

Gregg H. Alton, Senior VP/General Counsel

Dr. George P. Shultz, M.D., Other Corporate Officer

Dr.A. Bruce Montgomery, Senior VP, Divisional

Kristen M. Metza, Senior VP, Divisional

Robin L. Washington, CFO/Senior VP

Anthony D. Caracciolo, Divisional Senior VP

Dr.Taiyin Yang, Senior VP, Divisional

Board of Directors

Gayle E. Wilson, Director

Nicholas G. Moore, Director

Etienne F. Davignon, Director

Dr. Gordon E. Moore, M.D., Director

John W. Madigan, Director

Carla A. Hills, Director

Dr. Paul Berg, Director

Dr. George P. Shultz, M.D., Other Corporate Officer

John F. Cogan, Director

James M. Denny, Director

Dr. Richard J. Whitley, M.D., Director

Financials

Quarterly

Annual

Income Statement	07/2008	04/2008	01/2008	10/2007
Sales	265.68 Mil.	239.85 Mil.	215.54 Mil.	182.93 Mil.
Gross Operating Profit	1.01 Bil.	1.02 Bil.	879.18 Mil.	875.88 Mil.
Operating Income before D & A (EBITDA)	616.37 Mil.	668.05 Mil.	514.48 Mil.	562.56 Mil.
Total Income Before Interest Expenses (EBIT)	619.54 Mil.	690.75 Mil.	544.01 Mil.	576.53 Mil.
Total Net Income	442.83 Mil.	496.13 Mil.	401.64 Mil.	398.32 Mil.
Basic EPS, Total	0.48	0.53	0.43	0.43
Diluted EPS, Total	0.46	0.51	0.41	0.42

BALANCE STATEMENT	07/2008	04/2008	01/2008	10/2007
Cash and Equivalents	2.91 Bil.	2.59 Bil.	2.72 Bil.	584.13 Mil.
Total Assets	5.23 Bil.	NA	NA	2.55 Bil.
Total Liabilities	2.45 Bil.	939 Mil.	NA	691.44 Mil.
Total Capitalization	3.77 Bil.	3.33 Bil.	3.46 Bil.	4.4 Bil.

Cash Flow	07/2008	04/2008	01/2008	10/2007
Net Cash From Continuing Operations	NA	NA	NA	1.25 Bil.
Net Cash From Investing Activities	NA	NA	NA	-1.17 Bil.
Net Cash From Financing Activities	NA	NA	NA	-282.64 Mil.
Net Change in Cash & Cash Equivalents	NA	NA	NA	-231.88 Mil.

Income Statement	2008	2007	2006	2005
Sales	768.77 Mil.	386.04 Mil.	224.55 Mil.	142.18 Mil.
Gross Operating Profit	3.46 Bil.	2.64 Bil.	1.8 Bil.	1.18 Bil.
Operating Income before D & A (EBITDA)	2.16 Bil.	1.68 Bil.	1.15 Bil.	656.1 Mil.
Total Income Before Interest Expenses (EBIT)	2.27 Bil.	-624.11 Mil.	1.16 Bil.	663.77 Mil.
Total Net Income	1.62 Bil.	-1.19 Bil.	813.91 Mil.	449.37 Mil.
Basic EPS, Total	1.74	-1.3	0.9	0.52
Diluted EPS, Total	1.68	-1.3	0.86	0.5

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	2.72 Bil.	816.01 Mil.	707.91 Mil.	280.91 Mil.
Total Assets	NA	2.43 Bil.	3.09 Bil.	1.85 Bil.
Total Liabilities	NA	764.28 Mil.	455.34 Mil.	253.45 Mil.
Total Capitalization	3.46 Bil.	3.21 Bil.	3.27 Bil.	1.87 Bil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	NA	1.22 Bil.	715.08 Mil.	511.38 Mil.
Net Cash From Investing Activities	NA	-1.74 Bil.	-691.92 Mil.	-490.83 Mil.
Net Cash From Financing Activities	NA	649.26 Mil.	441.9 Mil.	78.66 Mil.
Net Change in Cash & Cash Equivalents	NA	108.09 Mil.	427 Mil.	86.19 Mil.

Gilead Sciences, Incorporated (GILD)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request